Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex
Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
To keep up to date with news from this category use our
Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
CAMBRIDGE, Mass., November 3, 2009 -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, announced today...
IRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM TWO PIVOTAL PHASE 3 TRIALS IN PATIENTS WITH CHRONIC CONSTIPATION
CAMBRIDGE, Mass. and New York, November 2, 2009 -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top line results from two Phase 3 clinical trials assessing the safety...
Movetis obtains EU authorisation for the commercialisation of Resolor
Turnhout, October 22, 2009 Movetis, the GI specialty pharmaceutical company based in Belgium, announces that it has obtained approval from the European Commission for the commercialisation of its lead product Resolor...
SciClone Announces Enrollment of First Patient in Its Phase 2 Trial of SCV-07 in Hepatitis C
FOSTER CITY, CA, Oct 21, 2009 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of its first patient at the Atlanta Gastroenterology Associates in Atlanta, GA, in a phase 2 trial of SCV-07...
Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes
Paris, France - October 21, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Wellstat Therapeutics Corporation announced today a global licensing agreement on PN2034, a novel oral first-in-class, insulin...
Intercell starts European Pivotal Phase III clinical trial for the patch-based Travelers' Diarrhea Vaccine
Vienna (Austria) and Gaithersburg (USA), October 14, 2009 - Intercell AG (VSE: ICLL) announced today that its Travelers' Diarrhea (TD) Vaccine Patch has entered clinical Phase III development. A pivotal efficacy field...
ImmunoCellular Therapeutics Announces Successful Humanization of Two Antibody Candidates
LOS ANGELES, CA -October 08, 2009 - ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers,...
Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-2125, a TLR9 Agonist, in Combination with Ribavirin for Chronic Hepatitis C Virus Infection
CAMBRIDGE, Mass.-- October 7, 2009-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in...
Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex
NATICK, Mass., Oct. 6 -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its WallFlex(
Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
SAN DIEGO, October 5, 2009 -- Conatus Pharmaceuticals Inc., a privately held, clinical stage company developing a treatment for liver disease associated with Hepatitis C Virus (HCV), announced today that Steven J....
Data Safety Monitoring Board Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancer
COLUMBIA, Md., Sep 21, 2009 -- Celsion Corporation (NASDAQ:CLSN) announced today the Data Safety Monitoring Board ("DSMB") has reviewed the safety data from the first group of patients enrolled in its pivotal...
Data Safety Monitoring Board Unanimously Recommends Continuation of Delcath's Phase III Clinical Trial
NEW YORK, Sept. 11 -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the Data and Safety...
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
MOUNTAIN VIEW, Calif., September 10, 2009 -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that it will present analysis of data from the efficacy portion of the first Phase 3 trial of its novel LEVADEX(TM)...
PTC THERAPEUTICS INITIATES REGISTRATION-DIRECTED PHASE 3 TRIAL OF ATALUREN IN CYSTIC FIBROSIS
SOUTH PLAINFIELD, NJ - September 10, 2009 - PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124
FDA Grants Protalix Orphan Drug Designation for prGCD
Sep. 8, 2009 -- Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that the FDA's Office of Orphan Products Development has...
Clavis Pharma ASA receives USD 1.1 million Grant from Innovation Norway
Oslo, Norway, 27 August 2009--Clavis Pharma ASA (OSE: CLAVIS) announced today that it has received a government grant of up to USD 1.1 mill (NOK 6.9 mill) to accelerate the Phase II clinical programme with Intravenous...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
